Aqueous two-phase emulsions-templated tailorable porous alginate beads for 3D cell culture.

A facile method was developed to produce porous alginate beads (PABs) with a controllable interconnected porous structure with aqueous two phase (ATPS) emulsions as template for 3D cell culture. ATPS emulsions, containing two biocompatible immiscible aqueous phases of cell/dextran (Dex) mixture and alginate (Alg)/polyethylene glycol (PEG) mixture and stabilized by mPEG-BSA particles, were introduced to form PABs. The pore size of PABs could be controlled by changing the emulsification frequency and the volume ratio between the ATPS emulsions and PEG-Alg solution. Moreover, cells could be directly encapsulated in the interconnected pores due to the excellent biocompatibility of ATPS. HeLa and human liver cancer cells encapsulated in the PABs present stronger cell activity (>95 %), proliferation, and enhanced functions compared with the cells encapsulated in general alginate beads (GABs). It is believed that the PABs is a promising microcarriers for 3D cell culture in vitro.

Predictors of fatal outcomes among hospitalized COVID-19 patients with pre-existing hypertension in China.

BACKGROUND: Coronavirus disease 2019 (COVID-19) is an emerging, rapidly evolving pandemic, hypertension is one of the most common co-existing chronic conditions and a risk factor for mortality. Nearly one-third of the adult population is hypertensive worldwide, it is urgent to identify the factors that determine the clinical course and outcomes of COVID-19 patients with hypertension. METHODS AND RESULTS: 148 COVID-19 patients with pre-existing hypertension with clarified outcomes (discharge or deceased) from a national cohort in China were included in this study, of whom 103 were discharged and 45 died in hospital. Multivariate regression showed higher odds of in-hospital death associated with high-sensitivity cardiac troponin (hs-cTn) > 28 pg/ml (hazard ratio [HR]: 3.27, 95% confidence interval [CI]: 1.55-6.91) and interleukin-6 (IL-6) > 7 pg/ml (HR: 3.63, 95% CI:1.54-8.55) at admission. Patients with uncontrolled blood pressure (BP) (n = 52) which were defined as systolic BP ≥140 mm Hg or diastolic BP ≥90 mm Hg for more than once (≥2 times) during hospitalization, were more likely to have ICU admission (p = 0.037), invasive mechanical ventilation (p = 0.028), and renal injury (p = 0.005). A stricter BP control with the threshold of 130/80 mm Hg was associated with lower mortality. Treatment with renin-angiotensin-aldosterone system (RAAS) suppressors, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), and spironolactone, was associated with a lower rate of ICU admission compared to other types of anti-hypertensive medications (8 (22.9%) vs. 25 (43.1%), p = 0.048). CONCLUSION: Among COVID-19 patients with pre-existing hypertension, elevated hs-cTn and IL-6 could help clinicians to identify patients with fatal outcomes at an early stage, blood pressure control is associated with better clinical outcomes, and RAAS suppressors do not increase mortality and may decrease the need for ICU admission.